AZD 0292
Alternative Names: AZD-0292Latest Information Update: 29 Apr 2024
At a glance
- Originator AstraZeneca
- Class Antibodies; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Bronchiectasis
Most Recent Events
- 09 Apr 2024 Phase-I clinical trials in Bronchiectasis (In volunteers) in USA (IV) (NCT06311760)
- 20 Mar 2024 Preclinical trials in Bronchiectasis in United Kingdom (IV) (Prior to March 2024)
- 15 Mar 2024 AstraZeneca plans a phase I trial (In volunteers) in the United Kingdom (IV, Infusion) (NCT06311760)